Cefepime-Enmetazobactam (formerly AA101; 30/20 µg) and Cefepime (30 µg) Disk Diffusion Quality Control Ranges Using a CLSI M23 (2018) Multi-Laboratory Study Design

Michael D. Huband1, Kelley A. Fedler1, Amy A. Watters1, A Belley2, Philipp Knechtle2, Robert K. Flamm1

ECCMID 2019 | ECCMID 2019, April 13–16, 2019, Amsterdam, the Netherlands

E. coli

Materials and Methods

1. The validated QC reference strains tested were Escherichia coli ATCC 25922 (K. pneumoniae), E. coli ATCC 35218 (K. pneumoniae), and Escherichia coli ATCC 700603 (P. aeruginosa), respectively

2. The CLSI disk diffusion QC ranges for cefepime (30 µg) and enmetazobactam (30/20 µg) were reevaluated in a multi-laboratory study.

Results

1. A total of 733 occurrences was obtained of cefepime-enmetazobactam (30/20 µg) disk diffusion range data which were approved at the January 2019 CLSI meeting for FPE, cefepime-enmetazobactam (30/20 µg).

Conclusion

- Established disk diffusion QC ranges for cefepime-enmetazobactam (30/20 µg) have recently entered phase II and should be considered for implementation, validation, and national endorsement.

References


SAS (Saint-Louis, France).

Contact

Michael D. Huband
jmilabs.com

SAS Institute Inc., Cary, North Carolina, USA.

To obtain a PDF of this poster:

To report any adverse event information: